Mebendazole plus lomustine or temozolomide in patients with recurrent ... @rakesh_jalali Nandini Menon Archya Dasgupta TMH Medical Oncology Alumni Vanita Noronha, MBBS MD DM Cancer Research, Statistics and Treatment Cancer Research and Statistics Foundation (CRSF) Sujith Dr Manuprasad sciencedirect.com/science/articl…

Congratulations Dr (Prof). Vijay Patil and the entire team for this promising paper..Inclusion of PS3 patients reflecting the real world scenario deserves special mention! Mebendazole plus lomustine or temozolomide in patients with recurrent ... sciencedirect.com/science/articl…

Congratulations Dr Manuprasad and all authors. Collaboration is key 🙏🏼 #ASCO22

Prashant Mehta Vanita Noronha, MBBS MD DM Dr (Prof). Vijay Patil Amol Patel bhawna sirohi I think science in India requires privilege as well & that breaks my heart every single day. Why isn’t it incentivised enough? Not talking about monetary incentives alone. Science & research should be encouraged. Environments should be made safe & conducive. We can do plenty. 🙂

ashayoncology Nirmal Raut Dr Manuprasad Bharat swaratika majumdar VIKAS TALREJA Dr Arun Chandran Dr.Avinash D Talele Vivek Agarwala. Great effort. Waiting for the results. Maybe #ASCO 2023

Congratulations Dr (Prof). Vijay Patil and team..Going to be truly practice changing especially in LMIC 👏

Thrilled to announce this online geriatric oncology teaching course organized by SIOG and Tata Memorial Hospital. Please register Anant Ramaswamy VIKRAM GOTA Dr Amol Akhade Venky Cancer and Aging Research Group (CARG) #GeriOnc #gerionc #geriheme

Proud moment # ASCO 2022# TMH . Very important trial for cisplatin in eligible patients

LBA6016. HN poster discussion. Poster board 8, Hall A in afternoon of 6th. For the first ever randomised study of low dose Nivolumab.Aju Mathew Bharat bhawna sirohi Sewanti Limaye 🇮🇳🇺🇸 Sampada Dessai Atul Sharma @BarbaraBurtness Open Oncology Cancer Research, Statistics and Treatment

Low dose Nivolumab Phase 3. #ASCO2022. Vanita Noronha, MBBS MD DM Nandini Menon Amol Patel Dr Amol Akhade @SachinD78722095 Deep Vora Bharat TMH Medical Oncology Alumni ATOM Coalition

Thanks Sujith for the share.This shows how important is to have our own data.Undoubtedly almost 70% of the cancers are related to lifestyle .But we need to dig deeper into the reasons for this difference within a small state !

Dr (Prof). Vijay Patil inspiring young researchers and doing a fantastic job of teaching research methodology. Nandini Menon Ashish Singh Dr Manuprasad Young Oncologists Group India🇮🇳

Sharing our experience with triple metronomic therapy as a preoperative therapy in oral cancer when there are prolonged waiting times ! Praveen Kumar Dr (Prof). Vijay Patil ecancer.org/en/journal/art…

Oncologists in LMIC should stop prescribing a neutropenic diet to cancer patients. Our study shows it does not reduce infection. BMJ SPCare Cancer Institute (WIA), Chennai Neutropenic versus regular diet for acute leukaemia induction chemotherapy: randomised controlled trial spcare.bmj.com/content/early/…

Only 60-70% of the 257 drugs approved for use in India over a decade are approved for use in major Western countries. It can only mean one of two things: that we are innovators in pharmaceuticals development or that our approval process is lax.

Very advanced age HNSCC can be cured. Age alone should not be criteria for pallaition Outcomes of curative Rx for head and neck squamous cell carcinoma in very elderly adults ≥80 years old onlinelibrary.wiley.com/doi/10.1002/he… Head and Neck Cancer International Group Cancer Research and Statistics Foundation (CRSF) Cancer Research, Statistics and Treatment Dr Manuprasad Vanita Noronha, MBBS MD DM

Congratulations Nikita Mehra for the excellent write up in the oncological contributions of the legendary Dr Muthulakshmi Reddy.

Thank you very much ESMO - Eur. Oncology for an excellent academic feast at ESMO asia ,Merit Travel grant and for the best poster award under Genitourinary -Prostate cancer category #ESMOAsia2022

ascopubs.org/doi/abs/10.120…. Phase 3 Docetaxel in Cisplatin unfit - is the most talked study. Email from Journal of Clinical Oncology says so. Thank you everyone for the appreciation. Nandini Menon Vanita Noronha, MBBS MD DM Dr Akhil Kapoor Anuj Kumar Anuja Abhyankar Dr Manuprasad Sewanti Limaye 🇮🇳🇺🇸 P. D. Hinduja Hospital Khar

1/n It is a dream of any medical oncologist to present at the podium at ASCO. I had that dream realised today to present the first multicentric investigator initiated trial from India.CRSF - Cancer Research and Statistic Foundation Dr (Prof). Vijay Patil Sameer Shrirangwar Nirmal Raut Dr Manuprasad ASCO #ASCO23